News
PTGX
39.30
-3.20%
-1.30
Weekly Report: what happened at PTGX last week (1216-1220)?
Weekly Report · 2d ago
Analysts Forecast 19% Gains Ahead For IJT
NASDAQ · 5d ago
Weekly Report: what happened at PTGX last week (1209-1213)?
Weekly Report · 12/16 11:25
Optimistic Buy Rating for Protagonist Therapeutics Driven by Promising Rusfertide Data and Strategic Takeda Partnership
TipRanks · 12/10 17:05
Protagonist Therapeutics Price Target Maintained With a $50.00/Share by HC Wainwright & Co.
Dow Jones · 12/10 13:02
HC Wainwright & Co. Reiterates Buy on Protagonist Therapeutics, Maintains $50 Price Target
Benzinga · 12/10 12:54
Protagonist Therapeutics: Promising Developments and Positive Outlook Justify Buy Rating
TipRanks · 12/10 12:17
Promising Prospects for Protagonist Therapeutics: Buy Rating Affirmed on Rusfertide’s Efficacy and Competitive Edge
TipRanks · 12/10 11:56
Analysts Are Bullish on Top Healthcare Stocks: AbbVie (ABBV), Protagonist Therapeutics (PTGX)
TipRanks · 12/10 11:40
Protagonist Therapeutics announces data from REVIVE study at ASH
TipRanks · 12/09 21:20
Weekly Report: what happened at PTGX last week (1202-1206)?
Weekly Report · 12/09 11:24
PROTAGONIST THERAPEUTICS INC <PTGX.O>: BMO INITIATES COVERAGE WITH OUTPERFORM RATING; PRICE TARGET $62
Reuters · 12/06 12:27
U.S. RESEARCH ROUNDUP-Doordash, Sagimet Biosciences, Ulta Beauty
Reuters · 12/06 07:14
Hold Rating Maintained for Protagonist Therapeutics Amid Promising Phase 3 Assets and Limited Financial Upside Due to Licensing Agreements
TipRanks · 12/05 22:25
Protagonist Therapeutics initiated with a Neutral at Goldman Sachs
TipRanks · 12/05 22:15
Buy Rating Affirmed for Protagonist Therapeutics: Innovative Peptide Platform and Promising Pipeline Drive Growth Prospects
TipRanks · 12/05 21:25
Weekly Report: what happened at PTGX last week (1125-1129)?
Weekly Report · 12/02 11:24
Insider Sale: Chief Medical Officer of $PTGX (PTGX) Sells 16,000 Shares
Barchart · 11/28 04:16
Protagonist Therapeutics (PTGX) Receives a Buy from Truist Financial
TipRanks · 11/25 12:09
Weekly Report: what happened at PTGX last week (1118-1122)?
Weekly Report · 11/25 11:15
More
Webull provides a variety of real-time PTGX stock news. You can receive the latest news about Protagonist Ther through multiple platforms. This information may help you make smarter investment decisions.
About PTGX
Protagonist Therapeutics, Inc. is a biopharmaceutical company. The Company uses its peptide-based chemical entities rusfertide and JNJ-2113 in different stages of development, all derived from its proprietary discovery technology platform. The Company’s clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its lead clinical asset, rusfertide (PTG-300), is an injectable hepcidin mimetic in development for the potential treatment of polycythemia vera (PV) and other blood disorders. The Company’s Interleukin-23 receptor (IL-23R) antagonist compound JNJ-2113 is an orally delivered investigational drug that is designed to block biological pathways targeted by marketed injectable antibody drugs. Its PN-943 is a wholly owned investigational orally delivered gut-restricted alpha 4 beta 7 (α4β7) specific integrin antagonist for inflammatory bowel disease (IBD).